Future IPO candidate

Elpiscience needs more funds for cancer research

Backed by Lilly Asia Ventures and Hillhouse, Elpiscience wants to attract more funding to develop the best-in-class solution for cancer treatment.

China-based immune-oncology company Elpiscience is currently raising Series B funding which it hopes to complete within the next couple of months.

¬ Haymarket Media Limited. All rights reserved.

Sign In to Your Account To Access Exclusive FinanceAsia Content!

Please sign in to your subscription to unlock full access to our premium FA resources.

Free Registration & 7-Day Trial
Register now to enjoy a 7-day free trial - no registration fees required. Click the link to get started.

Note: This free trial is a one-time offer.

Questions?
If you have any enquiries or would like a quote for a team or company licence, please contact us at [email protected]. Our subscription team will be happy to assist you.

Share our publication on social media
Share our publication on social media